Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-7888 with Checkpoint Inhibitors in Advanced Solid Tumors
NCT03311334Phase 2Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2017
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of adegramotide in renal cell carcinoma (RCC), urothelial carcinoma (UC), ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Sumitomo Pharma America. Started Dec 2017; status: terminated.
02
Drugs
adegramotide
03
Conditions
renal cell carcinoma (RCC)urothelial carcinoma (UC)ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03311334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311334.